{"preliminary_commentary":{"by_channel":{"youtube":34,"podcast":24,"x_thread":16},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05116189\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"KEYNOTE-B96","nct_id":"NCT05116189","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-b96-nct05116189. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","label":"Pembrolizumab + paclitaxel ± bevacizumab","type":"EXPERIMENTAL"},{"description":"Participants receive placebo via IV infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","label":"Placebo + paclitaxel ± bevacizumab","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-07-16","type":"ESTIMATED"},"conditions":["Ovarian Cancer","Carcinoma, Ovarian Epithelial","Fallopian Tube Neoplasms"],"enrollment":{"count":643,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475,","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["AVASTIN®, Zirabev"],"type":"DRUG"},{"name":"Placebo for pembrolizumab","otherNames":["normal saline or dextrose"],"type":"OTHER"},{"name":"Docetaxel","otherNames":["TAXOTERE®"],"type":"DRUG"}],"last_update":"2026-03-09","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-03-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥1)","timeFrame":"Up to ~38 months"},{"measure":"PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants","timeFrame":"Up to ~38 months"}],"references":[{"citation":"Lesnock JL, Temin S, Bouberhan S, Adams SF, Barber EL, Burkett WC, Corrales L, Fuh KC, Fujiwara K, Hardesty MM, Lefkowits C, Richardson K, Rimel BJ, Ring KL, Rocconi RP, Rungruang BJ, Scalici JM. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026 Oct;44(28):2725-2744. doi: 10.1200/JCO-26-01591. Epub 2026 Jul 13.","pmid":"42441925","type":"DERIVED"},{"citation":"Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026 Apr 18;407(10538):1525-1537. doi: 10.1016/S0140-6736(26)00602-1. Epub 2026 Apr 10.","pmid":"41974150","type":"DERIVED"},{"citation":"Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.","pmid":"37185961","type":"DERIVED"}],"start_date":{"date":"2021-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","url":"https://clinicaltrials.gov/study/NCT05116189"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-b96-nct05116189"}